Clinical Trials Logo

Clinical Trial Summary

Complementary and alternative medicine (CAM) is the term for medical products and/or practices that are not part of the current standard of care. Standard care is what medical doctors, doctors of osteopathy and allied health professionals, such as registered nurses and physical therapists, practice. Alternative medicine means treatments that you use instead of standard ones. Complementary medicine means nonstandard treatments that you use along with standard ones. The purpose of this study is to determine whether there is any improvement in symptoms reported by patients with chronic painful bladder syndrome when participating in alternative medical therapy/ exercise and meditative techniques. The specific alternative techniques participants will be randomized to in this trial include: Tai Chi instruction or walking exercise combined with sitting meditation.


Clinical Trial Description

Participants will be referred for trial screening if they have a diagnosis of painful bladder syndrome/IC in the opinion of the investigator. Participants will be required to read the informed consent form and sign it prior to the screening of any medical information. The eligibility criteria will be reviewed and participants who qualify will complete the visit one study screening procedures. Participants will be asked to track there daily pain level and medication use for 7 days prior to randomization an in addition will be required to complete one 24-hour void diary during this same screening time period. Participants will be asked to give a urine sample on the day of screening and the day of randomization to screen for bladder infection. Female participants will be asked to provide a urine sample for pregnancy testing prior to randomization. Participants will be required to be on a stable medical regime for 30 days prior to randomization. No new IC therapy or new pain treatments will be allowed to begin during the screening period and/or the 3 month study trial period. Participants will be allowed to continue on any IC/pain therapy they have used prior to screening. Randomization to the treatment groups will occur 5-7 days prior to treatment start date. At that visit the patient#s medical history will be reviewed for eligibility and adverse events. The recorded pain scores collected and all quality of life measurements obtained. Participants who continue to qualify will be randomized to the specified treatment group. Once 12 participants have been screened and are ready for randomization the participants will be scheduled for the randomization visit--Participants assigned to the Tai Chi group will be instructed on the logistics of the class, participants in this group will attend two classes/week- each class will be 1.5 hours in duration. The first 30 minutes will consist of standing meditation and progressive relaxation, the remaining 60 minutes will be TaiChi form instruction. The classes will meet bi-weekly for 3 months. Participants will be contacted by the blinded coordinator at 2 week intervals to assess pain level, medication use, and adverse event monitoring, all data will be documented. The exercise/meditation group will receive guided imagery CD and a pedometer to record the distance walked/bimonthly assessment. Participants will be asked to reserve 90 minutes twice weekly to complete the 30 min of walking exercise followed immediately by the 60 min of relaxation/mediation using the CD provided to them by the study. Participants will be asked to complete the exercise on the same days and times each week. The study coordinator will contact the participants every 2 weeks to assess pain level, medication use, and monitor for adverse events. Participants will not be responsible for the costs of the Tai Chi classes, pedometer, and relaxation-guided imagery CD. Participants will be required to provide the CD player; patients will not be eligible if they do not have access to one. Participants will not be reimbursed for travel costs to the Tai Chi classes. Participants will be seen in clinic for the end-point evaluation 3-7 days after 3 month treatment period. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00661050
Study type Observational
Source Stanford University
Contact
Status Withdrawn
Phase
Start date April 2008
Completion date December 2008

See also
  Status Clinical Trial Phase
Recruiting NCT02868775 - A Study to Determine the Role of Toll-like Receptor-4 Expression in Patients With Interstitial Cystitis/Bladder Pain Syndrome N/A
Completed NCT00672087 - Diagnostic Challenges in IC (and Male CPPS)
Completed NCT01482676 - The Role of microRNAs in Organ Remodeling in Lower Urinary Tract Dysfunction N/A
Terminated NCT00380783 - Safety and Efficacy of AGN 203818 for Pain Associated With Painful Bladder Syndrome/Interstitial Cystitis Phase 2
Completed NCT00775281 - Changes in Inflammatory and Contractile Protein Expression in Patients With Painful Bladder Syndrome/IC. N/A
Completed NCT05260112 - Smartphone-based Self-care Education Program for Women With Interstitial Cystitis: Educational Remote IC Aide N/A
Completed NCT05752344 - Interstitial Cystitis: Monitoring of the Psychic State and Counseling Intervention in the COVID-19 Era
Completed NCT01613586 - A Randomized Study Comparing Placebo and ASP3652 in the Treatment of Women With Bladder Pain Syndrome / Interstitial Cystitis (BPS/IC) Phase 2
Completed NCT02411110 - A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome Phase 2
Recruiting NCT06299683 - Pain Type and Interstitial Cystitis/Bladder Pain Syndrome Treatment N/A
Completed NCT00248664 - Events Preceding Interstitial Cystitis (EPIC) N/A
Completed NCT00601484 - An Effectiveness and Safety Study of PF-04383119 for the Treatment of Pain in Interstitial Cystitis Phase 2
Completed NCT02214550 - Chronic Pain Risk Associated With Menstrual Period Pain Phase 4
Completed NCT04275297 - Optimizing Psychosocial Treatment of Interstitial Cystitis/Bladder Pain Syndrome N/A
Terminated NCT00999518 - A Study To Investigate Tanezumab In Patients With Interstitial Cystitis/ Painful Bladder Syndrome Phase 2
Completed NCT00675298 - Linkage Analysis in Interstitial Cystitis N/A
Terminated NCT02781103 - Guided Imagery and Transcranial Direct Current Stimulation (tDCS) in Women With Chronic Pelvic Pain N/A
Recruiting NCT01074567 - DMSO Efficacy in IC/PBS Patients During and After Treatment N/A
Completed NCT02497976 - Pilot Study Evaluating the Efficacy of Certolizumab Pegol for Interstitial Cystitis Phase 3
Terminated NCT02787083 - A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis Phase 3